Hopefully getting some positive results through phase 2 will be enough for a further catalyst at some future point. At least they’re on the way with another product and indication.
Ann: PRENUMBRA formulation completed for clinical trial use, page-6
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.87 |
Change
-0.180(1.28%) |
Mkt cap ! $695.5M | |||
| Open | High | Low | Value | Volume |
| $14.00 | $14.11 | $13.75 | $449.0K | 32.22K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 437 | $13.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.89 | 170 | 6 |
View Market Depth
| Last trade - 12.23pm 20/08/2024 (20 minute delay) ? |
| CUV (ASX) Chart |